{'fraction_non_alphanumeric': 0.027472527472527472, 'fraction_numerical': 0.020879120879120878, 'mean_word_length': 6.1171875, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Therapy of a xenografted human colonic carcinoma using cisplatin or doxorubicin encapsulated in long‐circulating pegylated stealth liposomes

We compared the therapeutic effects of low doses of cisplatin and doxorubicin hydrochloride encapsulated in long‐circulating liposomes composed of cholesterol/hydrogenated soy phosphatidylcholine‐polyethylene glycol‐distearoyl‐phosphatidyl‐ethanolamine. The encapsulation of cisplatin and doxorubicin in these liposomes made ineffectively low doses of the free drugs able to inhibit the growth of and affect cures of a human colonic carcinoma growing in nude mice. Liposome‐encapsulated cisplatin had minor systemic toxic side effects indicated by an average 9% weight loss which was recovered 3–4 weeks after the last treatment. Toxicity was not observed in mice treated with liposome‐encapsulated doxorubicin. Int. J. Cancer 80:134–137, 1999. © 1999 Wiley‐Liss, Inc.